You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
通化東寶(600867.SH):可溶性甘精賴脯雙胰島素注射液申報臨牀獲得受理
格隆匯 12-27 15:41

格隆匯12月27日丨通化東寶(600867.SH)公佈,公司於近日取得國家藥品監督管理局藥品審評中心簽發的關於可溶性甘精賴脯雙胰島素注射液(THDB0207注射液)臨牀試驗申請受理通知書,受理號為CXSL2101513國。

可溶性甘精賴脯雙胰島素注射液屬於目前唯一能將長效甘精胰島素和速效賴脯胰島素成功組合的複方製劑。目前全球範圍內的雙胰島素產品僅有諾和諾德公司的德谷門冬雙胰島素注射液,(商品名稱:諾和佳、Ryzodeg),Ryzodeg於2012年起陸續在日本、歐洲和美國等多個地區上市,2019年5月在中國獲批上市,中文商品名為諾和佳。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account